Sandoz CEO Richard Saynor will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, detailing the company's strategy to lead what it calls the 'golden decade' of affordable medicines. The presentation follows two years of consistent progress since Sandoz became a standalone company in 2023, with the company now positioned to capture significant market share as reference medicines worth over USD 600 billion lose exclusivity in the coming decade. Saynor emphasized Sandoz's unique position as the only 'pure-play' biosimilar and generic company, noting that affordable medicines account for 80% of medicines used at just 30% of total healthcare costs.
Saynor stated that the company stands on the cusp of the biggest 'golden decade' in the history of the pharmaceutical industry, describing an unprecedented loss of exclusivity opportunity to increase patient access to needed medicines. The company has delivered on multiple strategic milestones since becoming independent, including breaking ground on a USD 1.1 billion sterile biosimilars production center in Brnik, Slovenia, and completing the acquisition of Just-Evotec Biologics' site in Toulouse, France. Sandoz also launched six biosimilars in 2025, with three coming in the fourth quarter alone, while investing USD 250 million in its vertically-integrated European production network for antibiotics.
With 2024 sales of USD 10 billion and strong double-digit growth in biosimilars, Sandoz maintains a robust financial position to support its investment plans. The company forecasts mid-single digit annual sales growth to 2028 at constant exchange rates, with core EBITDA margin expansion expected to reach 24% to 26% by 2028. Sandoz currently markets approximately 1,300 products in over 100 countries, supported by a pipeline of more than 400 assets. The coming decade presents two major opportunities: a USD 340 billion generic market where Sandoz targets nearly two-thirds of the total, and a USD 322 billion biosimilar market where the company aims for approximately 60% coverage.
A significant challenge remains the 'biosimilar void,' where more than 50 biologics facing loss of exclusivity in the next seven years currently have no biosimilar planned due to high clinical development costs. Sandoz has been leading industry efforts to streamline biosimilar development through regulatory changes that could substantially decrease both cost and time to market without compromising quality, safety, or efficacy. The company's presentation slides will be available after Saynor's presentation at https://www.sandoz.com/investors/events-presentations. A webcast of the presentation can be accessed at https://www.sandoz.com/investors/events-presentations/webcasts.
Saynor concluded that Sandoz is the global leader in an attractive, growing and system-critical market, poised to seize the unprecedented market opportunity over the next decade in the interests of shareholders, customers, partners and patients. The company's progress in its first two years as a standalone entity has created what management believes is the foundation for leading the affordable medicines sector through this transformative period. This strategic positioning matters because it addresses critical healthcare affordability challenges while capitalizing on a massive market shift as patents expire on hundreds of billions of dollars worth of medicines, potentially reshaping global pharmaceutical access and competition dynamics for years to come.
